262 related articles for article (PubMed ID: 27179720)
1. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
Shimada YJ; Cannon CP; Liu Y; Wilson C; Kupfer S; Menon V; Cushman WC; Mehta CR; Bakris GL; Zannad F; White WB;
Am Heart J; 2016 May; 175():18-27. PubMed ID: 27179720
[TBL] [Abstract][Full Text] [Related]
2. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
3. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
4. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Cavender MA; White WB; Liu Y; Massaro JM; Bergenstal RM; Mehta CR; Zannad F; Heller S; Cushman WC; Cannon CP
Clin Cardiol; 2018 Aug; 41(8):1022-1027. PubMed ID: 29652078
[TBL] [Abstract][Full Text] [Related]
5. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
[TBL] [Abstract][Full Text] [Related]
6. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Sharma A; Cannon CP; White WB; Liu Y; Bakris GL; Cushman WC; Zannad F
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29769203
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
9. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
Cavender MA; White WB; Jarolim P; Bakris GL; Cushman WC; Kupfer S; Gao Q; Mehta CR; Zannad F; Cannon CP; Morrow DA
Circulation; 2017 May; 135(20):1911-1921. PubMed ID: 28246236
[TBL] [Abstract][Full Text] [Related]
10. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
[TBL] [Abstract][Full Text] [Related]
12. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
13. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
15. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
Bergmark BA; Cannon CP; White WB; Jarolim P; Liu Y; Bonaca MP; Zannad F; Morrow DA
Diabetes Obes Metab; 2017 Jul; 19(7):962-969. PubMed ID: 28195387
[TBL] [Abstract][Full Text] [Related]
16. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
17. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
Barbery CE; Giczewska A; White J; Lokhnygina Y; Mentz RJ; Holman RR; Pagidipati N; Hernandez AF; Jones WS
Am Heart J; 2021 Sep; 239():59-63. PubMed ID: 33905751
[TBL] [Abstract][Full Text] [Related]
18. Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial.
Ferreira JP; Mehta C; Sharma A; Nissen SE; Rossignol P; Zannad F
BMC Med; 2020 Jun; 18(1):165. PubMed ID: 32493335
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Yabe D; Seino Y
Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
[TBL] [Abstract][Full Text] [Related]
20. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
